C13H19N3O3S
Neat
297.38
103296-32-8; NMP-ACA (Cefepime Impurity); NMP-ACA; (6R, 7R)-7-Amino-3-((1-methylpyrrolidinio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Cefepime amine derivative; (6R, 7R)-7-amino-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-Amino-3-((1-methylpyrrolidinio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, (6R, 7R)-; OXO94WH649; DE((2-aminothiazol-4-yl)-2-methoxyimino-acetyl)cefepime; UNII-OXO94WH649; Pyrrolidinium, 1-(((6R, 7R)-7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, inner salt; Pyrrolidinium, 1-((7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, inner salt and (6R-trans)-; Cefepime impurity E [EP]; Cefepime specified impurity E [EP]; Cefepime Impurity 23; Cefepime impurity E CRS; Cefepime dihydrochloride monohydrate impurity E [EP]; orb1697926; SCHEMBL8419897; DTXSID60145769
(6R and 7R)-7-amino-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
InChI=1S/C13H19N3O3S/c1-16(4-2-3-5-16)6-8-7-20-12-9(14)11(17)15(12)10(8)13(18)19/h9,12H,2-7,14H2,1H3/t9-,12-/m1/s1